HDAC-targeting epigenetic modulators for cancer immunotherapy

Binbin Cheng,Wei Pan,Yao Xiao,Zongbao Ding,Yingxing Zhou,Xiaoting Fei,Jin Liu,Zhenhong Su,Xiaopeng Peng,Jianjun Chen

DOI: https://doi.org/10.1016/j.ejmech.2024.116129

IF: 7.088

2024-01-12

European Journal of Medicinal Chemistry

Abstract:HDAC inhibitors, which can inhibit the activity of HDAC enzymes, have been extensively studied in tumor immunotherapy and have shown potential therapeutic effects in cancer immunotherapy. To date, numerous small molecule HDAC inhibitors have been identified, but many of them suffer from limited clinical efficacy and serious toxicity. Hence, HDAC inhibitor-based combination therapies, and other HDAC modulators (e.g. PROTAC degraders, dual-acting agents) have attracted great attention with significant advancements achieved in the past few years due to their superior efficacy compared to single-target HDAC inhibitors. In this review, we overviewed the recent progress on HDAC-based drug discovery with a focus on HDAC inhibitor-based drug combination therapy and other HDAC-targeting strategies (e.g. selective HDAC inhibitors, HDAC-based dual-target inhibitors, and PROTAC HDAC degraders) for cancer immunotherapy. In addition, we also summarized the reported co-crystal structures of HDAC inhibitors in complex with their target proteins and the binding interactions. Finally, the challenges and future directions for HDAC-based drug discovery in cancer immunotherapy are also discussed in detail.

chemistry, medicinal